NCT00160602已完成3 期
A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- UCB Pharma
- 入组人数
- 590
- 试验地点
- 70
- 主要终点
- Compare efficacy of two dose regimens of certolizumab pegol in combination with MTX to MTX alone in patients with RA measured by the ACR20 at week 24.
研究概览
简要总结
A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be at least 18 years old at the screening visit.
- •Patients must have a diagnosis of adult-onset RA of at least six months duration but not longer than fifteen years as defined by the 1987 American College of Rheumatology classification criteria.
- •Patients must have active RA disease as defined by:
- •9 tender joints at Screening and Baseline.
- •9 swollen joints at Screening and Baseline. and fulfilling 1 of the following 2 criteria during the screening period:
- •30 mm/hour ESR (Westergren), or CRP >15 mg/L.
- •Patients must have received treatment with MTX (with or without folic acid) for at least 6 months prior to the Baseline visit. The dose of MTX and route of administration must have been stable for at least 2 months prior to the baseline visit. The minimum stable dose of MTX allowed is 10 mg weekly.
- •Patients must be willing to complete an X-ray of the hands and feet 24 weeks after randomization even if they are no longer receiving study treatment in the present study, provided they have not withdrawn their informed consent.
排除标准
- •Patients must not have a diagnosis of any other inflammatory arthritis (e.g., psoriatic arthritis or ankylosing spondylitis).
- •Patients must not have a secondary, non-inflammatory type of arthritis (e.g. OA or fibromyalgia)
- •Female patients who are breast feeding, pregnant, or plan to become pregnant during the trial or for three months following last dose of study drug.
- •Patients with a history of tuberculosis or positive chest X-ray for tuberculosis or positive
- •Patients at a high risk of infection (e.g. leg ulcers, indwelling urinary catheter and persistent or recurrent chest infections and patients who are permanently bed ridden or wheelchair bound).
- •Patients with known human immunodeficiency virus (HIV) infection.
- •Patients with an active malignancy of any type or a history of malignancy (except basal cell carcinoma of the skin that has been excised prior to study start).
- •Patients with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the patient's participation in the trial.
- •Patients with a history of, or suspected, demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis).
结局指标
主要结局
Compare efficacy of two dose regimens of certolizumab pegol in combination with MTX to MTX alone in patients with RA measured by the ACR20 at week 24.
次要结局
- Assess Safety and Tolerability of two dose regimens of certolizumab pegol in combination with MTX and MTX alone in patients with RA; prevention of joint damage in patients with RA; Health Outcomes Measures
研究者
研究点 (70)
Loading locations...
相似试验
已完成
3 期
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer TherapyCancer Therapy-Related DiarrheaChemotherapy-related DiarrheaAdult Solid TumorProphylaxis of DiarrheaSymptomatic Relief of DiarrheaTargeted Therapy-related DiarrheaNCT04538625Napo Pharmaceuticals, Inc.287
撤回
3 期
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label ExtensionAlzheimer's DiseaseNCT04187547Cerecin
已完成
3 期
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)Multiple SclerosisNCT00404352Merck KGaA, Darmstadt, Germany517
已完成
3 期
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid ArthritisRheumatoid ArthritisNCT00152386UCB Pharma950
已完成
3 期
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal OsteoporosisPostmenopausal OsteoporosisNCT05087030Gedeon Richter Plc.473